Tonix Pharmaceuticals Holding Corp. — FY2012 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2012; the company is an early-stage CNS drug developer with no commercial products or product revenue. Its lead candidate, TNX-102 SL, is a low-dose sublingual cyclobenzaprine tablet being developed for fibromyalgia (FM) and post-traumatic stress disorder (PTSD). The company reported results on a consolidated basis, including its wholly owned subsidiaries.
Financial performance and liquidity
| Metric | FY2012 / Dec. 31, 2012 | FY2011 / Dec. 31, 2011 |
|---|---|---|
| Revenue and cost of goods sold | $0 | $0 |
| Research and development expense | $2.58 million | $1.16 million |
| General and administrative expense | $4.08 million | $2.22 million |
| Operating loss | $6.66 million | $3.38 million |
| Net loss | $9.45 million; $0.28 per share | $3.47 million; $0.16 per share |
| Cash used in operating activities | $5.71 million | $2.64 million |
| Cash and cash equivalents | $1.79 million | $41,123 |
| Working capital | $871,257 | Not stated |
| Total liabilities | $1.16 million | $2.88 million |
| Convertible debentures outstanding | $0 | $2.08 million |
Gross margin is not applicable because the company had no revenue or cost of goods sold. The filing reports no commercial cash flow and no operating profitability. Financing activities provided $7.49 million in cash during 2012, primarily through securities financings. Management estimated existing cash would cover operations for about six months and said approximately $2 million of additional funds would be needed for the following 12 months.
Material changes versus the prior year
- Net loss increased $5.98 million year over year, as R&D and G&A expenses rose with development activity, staffing, professional services and investor relations costs.
- Operating cash use more than doubled, while year-end cash increased from $41,123, principally due to equity and warrant financings.
- The 2012 net loss included a $1.18 million noncash charge from the change in fair value of warrant liabilities and $1.61 million of interest and other financing costs. The latter included a $710,000 beneficial conversion feature charge.
- Common shares outstanding increased from 27.1 million to 43.2 million during 2012. At year-end, 25.2 million warrants were outstanding, in addition to 3.0 million options; potential dilution is material.
Outlook, commentary and key risks
- Management planned to begin a potential Phase 2b FM trial in the third quarter of 2013, subject to funding and FDA concurrence. The planned study was expected to enroll 100–200 patients, with results anticipated in the second half of 2014.
- For PTSD, management planned to file an IND in the third quarter of 2013 and begin a Phase 2 proof-of-concept study in the fourth quarter of 2013. These are forward-looking plans, not completed milestones.
- The company intends to pursue a 505(b)(2) NDA pathway, but the FDA may require additional studies or a more extensive 505(b)(1) pathway. No NDA had been filed and no product had been approved.
- The independent auditor’s report included an explanatory paragraph stating that recurring losses, negative operating cash flows and the need for additional financing raise substantial doubt about the company’s ability to continue as a going concern. The financial statements were prepared on a going-concern basis.
- Management expected losses and R&D spending to rise. The company said it had no committed financing arrangements and warned that unavailable or unfavorable funding could force it to delay or reduce development, relinquish product rights, or curtail operations.
- Clinical efficacy and safety remain unproven in the target populations. Other significant risks include regulatory uncertainty, competition, patent challenges, dependence on third-party manufacturers and clinical research organizations, limited staff, related-party arrangements, reimbursement uncertainty, and thin trading in the OTCQB-listed stock.
Important facts for investors to verify
- Cash runway, subsequent financing, cash burn and whether the stated funding requirement was met.
- Progress, enrollment, results and FDA feedback for the planned TNX-102 SL FM and PTSD trials.
- Any changes to the auditor’s going-concern assessment and the company’s ability to maintain operations.
- Fully diluted share count, warrant exercise terms, registration rights and the potential impact of future securities issuance.
- Whether the FDA accepts the proposed 505(b)(2) pathway and what clinical and long-term safety evidence it requires.
- Related-party consulting fees, governance disclosures and any material changes in commercial, manufacturing or collaboration arrangements.